Sectors

Yale’s immunological and inflammatory disease therapy developer has filed for an offering with an $86.3m placeholder target.

Harvard's T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

European affiliates of Tencent provided nearly half of the $502m secured by the social network operator at a $2.1bn valuation earlier this month.

Prosus has led the on-demand home services provider’s latest round, which was reportedly secured at a $2bn valuation, pushing its total funding past $370m.

Exor, Coinbase Ventures and DRW Venture Capital have all invested in Crusoe Energy Systems, which owns a network of flared gas-powered data centres.

The Alphabet, Astellas, Novartis and WuXi AppTec-backed T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

Ant Group is the largest shareholder in the China-headquartered mobility services provider, which has chosen the US for its initial public offering.

Alphabet and Merck Group could exit the immunological and inflammatory disease therapy developer in an offering with an $86.3m placeholder target.

Carlyle Group has agreed to pay $435m for the biologics research technology provider, which has raised $86m from investors including Novo.

China Medical System and a WuXi Biologics industry investment fund were among the participants in the antibody therapy developer's $69.3m series A round.

The luxury goods reseller’s recently formed Valuence Ventures unit has chosen e-commerce services group Lingble for its first investment.